Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Air médical en bouteille, OXYGEN
Pari Pharma GmbH
Alternating Hemiplegia of Childhood
1 trial -
Albuterol DPI 25 mcg/inh
Amphastar France Pharmaceuticals
Asthma
1 trial -
Albuterol HFA-BOI
Teva Pharma GmbH
Asthma
1 trial -
Alicaforsen
IONIS PHARMACEUTICALS INC
Ulcerative Colitis
2 trials -
Alitretinoin
LIGAND PHARMACEUTICALS INC
Sarcoma, Kaposi
2 trials -
Alkotinib Capsules
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
ALK-positive Non-small Cell Lung Cancer
1 trial -
Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured
Pari Pharma GmbH
Adults diagnosed with SJS-TEN with at least 10% of body surface area involved
1 trial -
Alvelestat
Mereo BioPharma Group plc
Covid19
1 trial -
Alvelestat (MPH966)
Mereo BioPharma Group plc
Alpha-1 Antitrypsin Deficiency (AATD)
1 trial -
Amifampridine Phosphate
CATALYST PHARMACEUTICALS, INC.
Muscular Atrophy, Spinal
1 trial -
Amifampridine Phosphate 10 MG Oral Tablet
CATALYST PHARMACEUTICALS, INC.
Spinal Muscular Atrophy Type 3
1 trial -
Amphotericin B
Matinas BioPharma Holdings
Candidiasis, Chronic Mucocutaneous
1 trial -
Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection
Acumen Pharmaceuticals
Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)
1 trial -
An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies
Lacuna Pharma Pty Ltd
Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy
1 trial -
An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors
Ipsen
Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors
1 trial -
An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)
Swedish Orphan Biovitrum AB (publ)
Transplant-associated Thrombotic Microangiopathy (TA TMA)
1 trial -
An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes
Lacuna Pharma Pty Ltd
transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes
1 trial -
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
Pharming Technologies B.V.
Adult patients with primary mitochondrial disease
1 trial -
Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet
Lacuna Pharma Pty Ltd
Polymyalgia rheumatica
1 trial -
Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet
Lacuna Pharma Pty Ltd
Idiopathic membranous nephropathy and severe proteinuria
1 trial -
Aplindore
LIGAND PHARMACEUTICALS INC
Restless Legs Syndrome
1 trial -
Aplindore
LIGAND PHARMACEUTICALS INC
Early Stage Parkinson's Disease
1 trial -
Aramchol
Galmed Pharmaceuticals
Non-Alcoholic Fatty Liver Disease
1 trial -
Aramchol
Galmed Pharmaceuticals
Gallstones
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources